RA
AGRX

Royce & Associates’s Agile Therapeutics AGRX Stock Holding History

Royce & Associates’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45
Closed -$258K – 1083
2020
Q4 		$258K Hold
45
– – ﹤0.01% 947
2020
Q3 		$274K Hold
45
– – ﹤0.01% 907
2020
Q2 		$250K Hold
45
– – ﹤0.01% 921
2020
Q1 		$167K Buy
45
+5
+13% +$28.7K ﹤0.01% 936
2019
Q4 		$200K Hold
40
– – ﹤0.01% 969
2019
Q3 		$95K Hold
40
– – ﹤0.01% 994
2019
Q2 		$117K Hold
40
– – ﹤0.01% 1008
2019
Q1 		$121K Hold
40
– – ﹤0.01% 1014
2018
Q4 		$46K Hold
40
– – ﹤0.01% 1022
2018
Q3 		$29K Hold
40
– – ﹤0.01% 1107
2018
Q2 		$40K Hold
40
– – ﹤0.01% 1084
2018
Q1 		$206K Sell
40
-120
-75% -$793K ﹤0.01% 1087
2017
Q4 		$863K Sell
160
-321
-67% -$2.99M 0.01% 992
2017
Q3 		$4.29M Sell
481
-18
-4% -$138K 0.03% 625
2017
Q2 		$3.75M Buy
499
+5
+1% +$34.6K 0.02% 680
2017
Q1 		$3.17M Buy
494
+333
+207% +$1.67M 0.02% 727
2016
Q4 		$1.84M Hold
161
– – 0.01% 839
2016
Q3 		$2.25M Sell
161
-43
-21% -$614K 0.01% 770
2016
Q2 		$3.1M Buy
204
+41
+25% +$561K 0.02% 717
2016
Q1 		$2.02M Buy
163
+14
+9% +$181K 0.01% 825
2015
Q4 		$2.9M Hold
149
– – 0.02% 773
2015
Q3 		$2.01M Hold
149
– – 0.01% 871
2015
Q2 		$2.56M Sell
149
-79
-35% -$1.69M 0.01% 888
2015
Q1 		$4.22M Hold
228
– – 0.02% 779
2014
Q4 		$2.79M Buy
228
+63
+38% +$801K 0.01% 912
2014
Q3 		$2.4M Sell
165
-3
-2% -$46.3K 0.01% 970
2014
Q2 		$2.93M Buy
+168
New +$2.43M 0.01% 979

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

Royce & Associates's AGRX Position: Q1 2021 in Review

Royce & Associates sold out of Agile Therapeutics (AGRX) in Q1 2021, closing a stake of 45 shares — an estimated $258K sold.

Royce & Associates first reported a position in AGRX in Q2 2014 and held it in 27 quarters. The position peaked at $4.29M in Q3 2017. 73 funds tracked by Wall St. Rank hold AGRX as of Q1 2021.

  • Royce & Associates reported no remaining Agile Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Royce & Associates sold 45 Agile Therapeutics shares in Q1 2021, an estimated $258K.
  • Royce & Associates first reported a position in Agile Therapeutics in Q2 2014 and held it in 27 quarters.
  • Royce & Associates's Agile Therapeutics position peaked at $4.29M in Q3 2017.
  • 73 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2021.

Based on Royce & Associates's 13F filing for Q1 2021, filed 10 May 2021.